Alvotech (NASDAQ:ALVO) Releases Quarterly Earnings Results, Misses Estimates By $0.19 EPS

Alvotech (NASDAQ:ALVO) announced its quarterly earnings results on Wednesday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.19), Zacks reports.

Alvotech Stock Up 0.8%

Alvotech stock traded up $0.04 during mid-day trading on Wednesday, hitting $4.92. 779,973 shares of the company’s stock traded hands, compared to its average volume of 765,719. Alvotech has a one year low of $2.94 and a one year high of $6.53. The firm has a 50 day moving average price of $5.28 and a 200 day moving average price of $4.21. The company has a market cap of $1.48 billion, a PE ratio of -8.07 and a beta of 0.24.

Analysts Set New Price Targets

ALVO has been the topic of a number of analyst reports. UBS Group set a $8.00 price objective on shares of Alvotech in a report on Wednesday, September 16th. Zacks Research lowered shares of Alvotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Barclays raised shares of Alvotech from an “underweight” rating to an “overweight” rating and boosted their target price for the company from $4.00 to $8.00 in a research note on Wednesday, September 16th. Bank of America began coverage on shares of Alvotech in a research report on Monday, August 24th. They issued a “buy” rating and a $7.00 target price for the company. Finally, Wall Street Zen lowered shares of Alvotech from a “hold” rating to a “sell” rating in a research note on Saturday. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.40.

Top Alvotech Stories

Here are a few of the latest stories about ALVO:

• Positive Sentiment: Third-quarter product and service revenue rose 78% year over year to $58.2 million, while adjusted EBITDA more than doubled to $31.5 million. The FDA also accepted Alvotech’s application for its proposed Entyvio biosimilar, and approved Simlandi manufacturing changes that more than double output per batch. Alvotech financial results and business update
• Positive Sentiment: Jefferies initiated coverage with a Buy rating and a $9 price target, which may support sentiment toward the shares. Jefferies initiates Alvotech at Buy
• Neutral Sentiment: Alvotech maintained 2026 revenue guidance of $650 million–$700 million and EBITDA guidance of $180 million–$220 million. The revenue range is broadly in line with the $652.5 million consensus estimate, though management expects results toward the lower end.

Alvotech Company Profile

Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.